ulcerative colitis and glp 1 Ozempic colitis: Possible benefits and risks The role of GLP-1 RA

Total Neoadjuvant Therapy approach: A Shifting Paradigm in Locally Advanced Rectal Cancer

The time to plan is now As new uses for GLP-1 medications arise, we believe plan sponsors should start preparing now for increased demand and develop a program approach that balances appropriate access with maintaining benefit affordability

Week 1-2 Protocol: Begin with 100mcg administered once daily Optimal timing: morning administration on an empty stomach Monitor and document any observable changes Maintain consistent injection sites (rotating between abdomen, thighs) Week 3-4 Adjustment: If well-tolerated, increase to 150mcg daily Continue once-daily administration schedule Assess response patterns and document findings Consider splitting dose if preferred (75mcg twice daily) The subcutaneous route of administration remains the gold standard for KLOW blend peptide delivery

Look for 503B outsourcing facility status (FDA-registered and inspected) or PCAB accreditation